VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 40 filers reported holding VERONA PHARMA PLC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,646,033 | -50.8% | 223,683 | -36.1% | 0.00% | 0.0% |
| Q2 2023 | $7,404,623 | +23.1% | 350,266 | +17.0% | 0.00% | 0.0% |
| Q1 2023 | $6,012,916 | +12.5% | 299,448 | +46.4% | 0.00% | 0.0% |
| Q4 2022 | $5,343,585 | -31.9% | 204,500 | -73.4% | 0.00% | -50.0% |
| Q3 2022 | $7,845,000 | +3182.4% | 767,560 | +1247.8% | 0.00% | – |
| Q2 2022 | $239,000 | +223.0% | 56,949 | +282.2% | 0.00% | – |
| Q1 2022 | $74,000 | -55.2% | 14,900 | -39.4% | 0.00% | – |
| Q4 2021 | $165,000 | +32.0% | 24,589 | +7.5% | 0.00% | – |
| Q3 2021 | $125,000 | +26.3% | 22,870 | +93.8% | 0.00% | – |
| Q1 2021 | $99,000 | -47.6% | 11,800 | -56.1% | 0.00% | – |
| Q4 2020 | $189,000 | +177.9% | 26,900 | +148.5% | 0.00% | – |
| Q1 2019 | $68,000 | – | 10,824 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |